Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Damiani, Giovanni, Odorici, Giulia, Pacifico, Alessia, Morrone, Aldo, Conic, Rosalynn R. Z., Davidson, Tima, Watad, Abdulla, Pigatto, Paolo D. M., Colombo, Delia, Malagoli, Piergiorgio, Fiore, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780469/
https://www.ncbi.nlm.nih.gov/pubmed/35056153
http://dx.doi.org/10.3390/ph15010095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780469/
https://www.ncbi.nlm.nih.gov/pubmed/35056153
http://dx.doi.org/10.3390/ph15010095

Ejemplares similares